|
[1]Group of Pancreas Surgery, Chinese Society of Surgery, Chinese Medical Association.Guidelines for the management of pancreatic cancer[J].Chin J Pract Surg, 2007, 27 (9) :671-673. (in Chinese) 中华医学会外科学分会胰腺外科学组.胰腺癌诊治指南[J].中国实用外科杂志, 2007, 27 (9) :671-673.
|
|
[2]LI ZS.Status and prospects of early diagnosis of pancreatic cancer[J].J Clin Hepatol, 2010, 26 (5) :451-458. (in Chinese) 李兆申.胰腺癌早期诊断研究现状及展望[J].临床肝胆病杂志, 2010, 26 (5) :451-458.
|
|
[3]JEMAL A, SIEGEL R, WARD E, et al.Cancer Statistics, 2009[J].CA Cancer J Clin, 2009, 59 (4) :225-249.
|
|
[4]CALLEWAERT N, GEYSENS S, MOLEMANS F, et al.Ultrasensitive profiling and sequencing of N-linked oligosaccharides using standard DNA-sequencing equipment[J].Glycobiology, 2001, 11 (4) :275-281.
|
|
[5]CHEN C, SCHMILOVITZ-WEISS H, LIU XE, et al.Serum protein N-Glycans profiling for the discovery of potential biomarkers for nonalcoholic steatohepatitis[J].J Proteome Res, 2009, 8 (2) :463-470.
|
|
[6]LIU XE, DESMYTER L, GAO CF, et al.N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus[J].Hepatology, 2007, 46 (5) :1426-1435.
|
|
[7]GENG F, WU XZ.Research advances inα-1, 6-fucosyltransferase[J].Chem Life, 2003, 23 (2) :118-120. (in Chinese) 耿飞, 吴兴中.α-1, 6岩藻糖基转移酶的研究进展[J].生命的化学, 2003, 23 (2) :118-120.
|
|
[8]CUI W, XU XH.Clinical value of combined measurement of serumCA19-9, CA242, CEA, and LAP in diagnosis of pancreatic cancer[J].J Radioimmunol, 2011, 24 (3) :353-355. (in Chinese) 崔巍, 徐笑红.血清CA19-9、CA242、CEA、LAP联检诊断胰腺癌的临床价值[J].放射免疫学杂志, 2011, 24 (3) :353-355.
|
|
[9]CHEN D, FAN YH.Clinical value and limitations of serum CA19-9 as a biomarker of pancreatic cancer[J].J Clin Hepatol, 2013, 29 (3) :239-240. (in Chinese) 陈达, 樊艳华.CA19-9在胰腺癌中的应用价值及局限性[J].临床肝胆病杂志, 2013, 29 (3) :239-240.
|
|
[10]GUO XZ.Progress in medical diagnosis and treatment of pancreatic cancer[J].Chin J Pancreatol, 2013, 13 (3) :145-146. (in Chinese) 郭晓钟.胰腺癌内科诊治进展[J].中华胰腺病杂志, 2013, 13 (3) :145-146.
|
DownLoad: